EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Subtyping and Therapeutic Targeting of IFNG ‐Driven Immunogenic Cell Death in Lung Adenocarcinoma

Lifeng Li, Yaqi Yang, Mengle Peng iD, Biyue Wang, Lili Zhu, Chengxin Chen, Zhirui Fan, Xiaoran Duan, Ruyue Xue, Xuefeng Lv, Ming Cheng, Jie Zhao iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70678 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Lifeng Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Laboratory for Internet Medical Systems and Applications, the First Affiliated Hospital of Zhengzhou University, Zhengzhou Unive…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Interferon-gamma, Lung Neoplasms, Immunogenic Cell Death. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund, Key scientific research project plan of colleges and universities in Henan Province, Wu Jieping Medical Foundation Special Fund for Targeted Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunogenic cell death (ICD) can be triggered by various therapies to induce anti‐tumor immune responses, significantly enhancing treatment effectiveness, and is widely utilized in tumor immunotherapy.

Methods

LUAD data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) validated ICD‐related molecular subtypes via consensus clustering. Clinical features, ICD genes, driver genes, mutations, tumor microenvironment, immune checkpoints, and drug sensitivity were compared. RT‐qPCR, Western blot, immunofluorescence, ELISA, flow cytometry, and tube formation assays validated findings.

Results

Differential expression of 33 ICD genes was observed between tumor and normal tissues. These genes were clustered into two groups via consensus clustering and validated with GEO data. Prognostic analysis indicated superior outcomes in cluster 2 across TCGA and GEO cohorts. Significant disparities in clinicopathological characteristics like stage, gender, and age were noted between subtypes. Cluster 2 exhibited heightened expression of ICD‐related genes, driver genes, immune checkpoints, and immune cells. Cluster 2 also showed increased sensitivity to chemotherapy drugs. IFNG overexpression in A549 and H1299 cells induced CRT exposure, HMGB1 release, and ATP secretion, thereby promoting dendritic cell maturation and enhancing CD8+ T cell function. Additionally, IFNG boosted tumor angiogenesis via HMGB1 pathways, which could be mitigated by HMGB1 inhibition.

Conclusion

Identification of novel ICD‐related molecular subtypes holds promise for guiding personalized therapies, assessing prognosis, and predicting immunotherapy efficacy in LUAD. IFNG emerges as a potential prognostic biomarker and therapeutic target, influencing both the tumor microenvironment and angiogenesis. These findings offer new insights into therapeutic strategies targeting IFNG‐mediated pathways in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungInterferon-gammaLung NeoplasmsImmunogenic Cell DeathHumansTumor MicroenvironmentFemalePrognosisMaleHMGB1 ProteinGene Expression Regulation, NeoplasticBiomarkers, TumorCell Line, TumorMiddle Aged

Stichwörter der Autor:innen

IFNGimmunogenic cell deathlung adenocarcinomamolecular subtypestumor microenvironment

Substanzen

Interferon-gammaIFNG protein, humanHMGB1 ProteinBiomarkers, TumorHMGB1 protein, human

Autor:innen und Institutionen

  • National Engineering Laboratory for Internet Medical Systems and Applications, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
  • Cancer Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, China.
  • Medical School, Huanghe Science and Technology University, Zhengzhou, Henan, China.
  • Fuwai Central China Cardiovascular Hospital, Internet Medical and System Applications of National Engineering Laboratory, Zhengzhou, Henan, China.
  • Department of Clinical Laboratory, Henan No. 3 Provincial People's Hospital, Zhengzhou, Henan, China.
  • College of Public Health, Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Mengle Peng, Jie Zhao

Förderung

  • State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia Fund
  • Key scientific research project plan of colleges and universities in Henan Province
  • Wu Jieping Medical Foundation Special Fund for Targeted Cancer Research
  • Funding for Scientific Research and Innovation Team of The First Affiliated Hospital of Zhengzhou University
  • Henan Key Laboratory of Chronic Disease Management
  • National Science Foundation of China
  • National Natural Science Foundation of China

Zitieren

APA

Li, L., Yang, Y., Peng, M., Wang, B., Zhu, L., Chen, C., Fan, Z., Duan, X., Xue, R., Lv, X., Cheng, M., & Zhao, J. (2025). Molecular Subtyping and Therapeutic Targeting of IFNG ‐Driven Immunogenic Cell Death in Lung Adenocarcinoma. Cancer Medicine. https://doi.org/10.1002/cam4.70678

Vancouver

Li L, Yang Y, Peng M, Wang B, Zhu L, Chen C, et al. Molecular Subtyping and Therapeutic Targeting of IFNG ‐Driven Immunogenic Cell Death in Lung Adenocarcinoma. Cancer Medicine. 2025. doi:10.1002/cam4.70678

BibTeX
@article{Li2025,
  author = {Li, Lifeng and Yang, Yaqi and Peng, Mengle and Wang, Biyue and Zhu, Lili and Chen, Chengxin and Fan, Zhirui and Duan, Xiaoran and Xue, Ruyue and Lv, Xuefeng and Cheng, Ming and Zhao, Jie},
  title = {Molecular Subtyping and Therapeutic Targeting of IFNG ‐Driven Immunogenic Cell Death in Lung Adenocarcinoma},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70678}
}
Kostenlos starten →